Fmoc-Leu-OH

CAS# 35661-60-0

Fmoc-Leu-OH

Catalog No. BCC3509----Order now to get a substantial discount!

Product Name & Size Price Stock
Fmoc-Leu-OH: 5mg $6 In Stock
Fmoc-Leu-OH: 10mg Please Inquire In Stock
Fmoc-Leu-OH: 20mg Please Inquire Please Inquire
Fmoc-Leu-OH: 50mg Please Inquire Please Inquire
Fmoc-Leu-OH: 100mg Please Inquire Please Inquire
Fmoc-Leu-OH: 200mg Please Inquire Please Inquire
Fmoc-Leu-OH: 500mg Please Inquire Please Inquire
Fmoc-Leu-OH: 1000mg Please Inquire Please Inquire
Related Products
  • PF-4708671

    Catalog No.:BCC5031
    CAS No.:1255517-76-0
  • BIX 02565

    Catalog No.:BCC4303
    CAS No.:1311367-27-7
  • BI-D1870

    Catalog No.:BCC5030
    CAS No.:501437-28-1
  • CMK

    Catalog No.:BCC1489
    CAS No.:821794-90-5

Quality Control of Fmoc-Leu-OH

Number of papers citing our products

Chemical structure

Fmoc-Leu-OH

3D structure

Chemical Properties of Fmoc-Leu-OH

Cas No. 35661-60-0 SDF Download SDF
PubChem ID 4308 Appearance Powder
Formula C21H23NO4 M.Wt 353.4
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO with gentle warming
Chemical Name 2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid
SMILES CC(C)CC(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
Standard InChIKey CBPJQFCAFFNICX-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Fmoc-Leu-OH

DescriptionAnti-inflammatory agent; increases intracellular Ca2+ levels.

Fmoc-Leu-OH Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Fmoc-Leu-OH Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Fmoc-Leu-OH

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8297 mL 14.1483 mL 28.2965 mL 56.5931 mL 70.7414 mL
5 mM 0.5659 mL 2.8297 mL 5.6593 mL 11.3186 mL 14.1483 mL
10 mM 0.283 mL 1.4148 mL 2.8297 mL 5.6593 mL 7.0741 mL
50 mM 0.0566 mL 0.283 mL 0.5659 mL 1.1319 mL 1.4148 mL
100 mM 0.0283 mL 0.1415 mL 0.283 mL 0.5659 mL 0.7074 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Fmoc-Leu-OH

Fmoc-Leu-OH

Featured Products
New Products
 

References on Fmoc-Leu-OH

NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells.[Pubmed:10857466]

Chin J Physiol. 2000 Mar 31;43(1):29-33.

This report demonstrates that NPC-15199 [(N-(9-fluorenylmethoxycarbonyl)L-leucine)], a novel anti-inflammatory agent, increases intracellular Ca2+ concentration ([Ca2+]i) in human bladder female transitional cancer (BFTC) cells. Using fura-2 as a Ca2+ probe, NPC-15199 (0.1-2 mM) was found to increase [Ca2+]i concentration-dependently. The response saturated at 2-5 mM NPC-15199. The [Ca2+]i increase comprised an initial rise, a slow decay, and a plateau. Ca2+ removal partly inhibited the Ca2+ signals. In Ca2+-free medium, pretreatment with 1 mM NPC-15199 abolished the [Ca2+]i increase induced by 1 microM thapsigargin (an endoplasmic reticulum Ca2+ pump inhibitor); and after pretreatment with thapsigargin, NPC-15199-induced Ca2+ release was dramatically inhibited. This indicates that NPC-15199 released internal Ca2+ mostly from the endoplasmic reticulum. Adding 3 mM Ca2+ increased [Ca2+]i in cells pretreated with 1 mM NPC-15199 in Ca2+-free medium. Together, the findings suggest that in BFTC bladder cancer cells, NPC-15199 induced Ca2+ release from the endoplasmic reticulum and activating Ca2+ entry.

Guinea pig ileitis is attenuated by the leumedin N-(fluorenyl-9- methoxycarbonyl)-leucine (NPC 15199).[Pubmed:8392562]

J Pharmacol Exp Ther. 1993 Jul;266(1):468-72.

Anti-inflammatory properties have been ascribed to a series of N-(fluorenyl-9-methoxycarbonyl) amino acids called leumedins that inhibit the activity of granulocytes and T-lymphocytes. We evaluated one of these leumedins, N-(fluorenyl-9-methoxycarbonyl) leucine (NPC 15199), in a model of ileitis in guinea pigs. Ileitis was induced by intraluminal trinitrobenzenesulfonic acid (TNBS 30 mg/kg in 50% ethanol) in anesthetized guinea pigs. NPC 15199 was administered daily (10 or 100 mg/kg, s.c.). After 7 days, the guinea pigs were anesthetized, and saline was administered intraluminally into an ileal loop created at the site of TNBS administration and was withdrawn after 30 min. The changes in lavage protein, nitrite levels, myeloperoxidase (MPO) activity and mast cell numbers were used as indices of inflammation and injury. NPC 15199 (10 or 100 mg/kg) attenuated or abolished TNBS-induced elevations in lavage protein and nitrite content. Only the high dose of NPC 15199 (100 mg/kg) attenuated ileal MPO activity and mast cell hyperplasia. Histological disturbances induced by TNBS administration included crypt hypertrophy, mucosal and submucosal fibrosis and smooth-muscle hyperplasia. These disturbances were reversed by high-dose NPC 15199 (100 mg/kg) but were minimally affected by low-dose NPC 15199 (10 mg/kg). We conclude that NPC 15199 prevents mucosal injury and dysfunction in this model of intestinal inflammation. Inhibition of granulocyte infiltration does not appear to be essential for the beneficial effects of NPC 15199 and suggests that the alternative actions of NPC 15199 may be pertinent to this model.

N-(fluorenyl-9-methoxycarbonyl) amino acids, a class of antiinflammatory agents with a different mechanism of action.[Pubmed:1824872]

Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):355-9.

Several members of a series of N-(fluorenyl-9-methoxycarbonyl) amino acids were found to possess a broad spectrum of antiinflammatory activity. The compounds were active against oxazolone dermatitis in mice and adjuvant arthritis in rats, models in which activated T lymphocytes are implicated. The compounds also inhibited T-lymphocyte activation in vitro, assessed by using the mixed lymphocyte reaction. The compounds inhibited the reversed passive Arthus reaction in rats and arachidonic acid-induced dermatitis in mice, models in which leukocyte infiltration is responsible for the inflammatory reaction. More complete evaluation was made of one compound, N-(fluorenyl-9-methoxycarbonyl)leucine (NPC 15199). On histologic examination after arachidonic acid administration, NPC 15199 was found to block recruitment of neutrophils into the inflammatory site. The compound was not a general myelotoxin. Prolonged treatment of animals did not alter bone-marrow progenitor number or the numbers of circulating white blood cells. Further, several white cell functions were not inhibited in vitro, including neutrophil respiratory burst and macrophage phagocytosis. NPC 15199 was effective in blocking antigen arthritis in rabbits and was effective in a therapeutic protocol, reversing oxazolone edema. These studies suggest that N-(fluorenyl-9-methoxycarbonyl) amino acids may be valuable therapeutic agents for inflammatory diseases.

Keywords:

Fmoc-Leu-OH,35661-60-0,Natural Products,Fmoc-Amino Acids and Derivatives, buy Fmoc-Leu-OH , Fmoc-Leu-OH supplier , purchase Fmoc-Leu-OH , Fmoc-Leu-OH cost , Fmoc-Leu-OH manufacturer , order Fmoc-Leu-OH , high purity Fmoc-Leu-OH

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: